
## Eli N Deal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7976007/publications.pdf Version: 2024-02-01



| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Predictors of Treatment Failure Following De-escalation to a Fluoroquinolone in Culture-Negative<br>Nosocomial Pneumonia. Annals of Pharmacotherapy, 2019, 53, 1207-1213.                              | 1.9 | 1         |
| 2  | Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation. Journal of the<br>American Society of Nephrology: JASN, 2017, 28, 1957-1959.                                     | 6.1 | 6         |
| 3  | Weightâ€based insulin dosing for acute hyperkalemia results in less hypoglycemia. Journal of Hospital<br>Medicine, 2016, 11, 355-357.  | 1.4 | 34        |
| 4  | Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients. Annals of<br>Pharmacotherapy, 2016, 50, 824-831.  | 1.9 | 4         |
| 5  | Impact of Vitamin K Administration on INR Changes and Bleeding Events Among Patients With<br>Cirrhosis. Annals of Pharmacotherapy, 2016, 50, 113-117.  | 1.9 | 20        |
| 6  | Analysis of Enoxaparin Dose Titration at a Large, Tertiary Teaching Facility. Clinical and Applied<br>Thrombosis/Hemostasis, 2015, 21, 720-723.  | 1.7 | 0         |
| 7  | Apixaban Use Among Patients With Severe Renal Impairment. Annals of Pharmacotherapy, 2014, 48,<br>1667-1667.   | 1.9 | 23        |
| 8  | Safety and Efficacy of Hyperglycemia Urgency Order Set. Journal of Diabetes Science and Technology, 2014, 8, 1062-1063.  | 2.2 | 0         |
| 9  | Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and<br>Haemostasis, 2014, 111, 88-93.   | 3.4 | 120       |
| 10 | Consider a Patient's Weight and the Weight of the Evidence When Calculating Renal Function. Annals of Pharmacotherapy, 2013, 47, 908-909.  | 1.9 | 4         |
| 11 | Assessment of Bleeding Events Associated With Short-Duration Therapeutic Enoxaparin Use in the<br>Morbidly Obese. Annals of Pharmacotherapy, 2013, 47, 1641-1648.                                      | 1.9 | 11        |
| 12 | Role of New Drugs for Management of Atrial Fibrillation. Annals of Pharmacotherapy, 2012, 46,<br>1656-1670.  | 1.9 | 2         |
| 13 | Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous<br>Thromboembolism in Morbidly Obese Inpatients Blood, 2012, 120, 2268-2268.                                       | 1.4 | 0         |
| 14 | Implementation of a real-time computerized sepsis alert in nonintensive care unit patients*. Critical<br>Care Medicine, 2011, 39, 469-473.   | 0.9 | 145       |
| 15 | Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. Journal of Thrombosis and Thrombolysis, 2011, 32, 188-194. | 2.1 | 36        |
| 16 | Inpatient insulin orders: Are patients getting what is prescribed?. Journal of Hospital Medicine, 2011, 6,<br>526-529.   | 1.4 | 18        |
| 17 | Comparison of Bivalirudin and Argatroban for the Management of Heparinâ€Induced Thrombocytopenia.<br>Pharmacotherapy, 2010, 30, 1229-1238.   | 2.6 | 52        |
| 18 | Identifying Optimal Initial Infusion Rates for Unfractionated Heparin in Morbidly Obese Patients.<br>Annals of Pharmacotherapy, 2010, 44, 1141-1151.   | 1.9 | 41        |

Eli N Deal

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Characteristics of patients with morbid obesity at an academic medical center. American Journal of<br>Health-System Pharmacy, 2010, 67, 1589-1590.  | 1.0 | 7         |
| 20 | Reply: Identifying Optimal Initial Infusion Rates for Unfractionated Heparin in Morbidly Obese Patients.<br>Annals of Pharmacotherapy, 2010, 44, 2038-2039.   | 1.9 | 0         |
| 21 | Contraindicated Medication Use in Dialysis Patients. JAMA - Journal of the American Medical Association, 2010, 303, 1481-1482.  | 7.4 | 1         |
| 22 | Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by<br>Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: A single-center, open-label,<br>prospective, observational study. Clinical Therapeutics, 2009, 31, 299-310. | 2.5 | 12        |
| 23 | Role of corticosteroids in the management of acute respiratory distress syndrome. Clinical Therapeutics, 2008, 30, 787-799.   | 2.5 | 36        |
| 24 | Delayed-Onset Neutropenia with Divalproex Sodium. Annals of Pharmacotherapy, 2008, 42, 1507-1510.   | 1.9 | 14        |
| 25 | Predictors of In-Hospital Mortality for Bloodstream Infections Caused byEnterobacterSpecies orCitrobacter freundii. Pharmacotherapy, 2007, 27, 191-199.   | 2.6 | 37        |